Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Recovery ⢠Tight Liquidity ⢠Heavy Leverage FTRE's improving profitability and positive free cash flow are encouraging, but high leverage, tight liquidity, and weak interest coverage keep the stock high-risk despite its low sales multiple.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Resistance Capping ⢠Recent Weakness Support Level: $17.40â$17.60 Resistance Level: $18.60â$18.90 FTRE was flat but recently weak last month, with $17.40â$17.60 support and $18.60â$18.90 resistance; watch for a break below support or sustained move above resistance.
Sentiment & News
Key News Insights: ⢠EBITDA Expansion ⢠Booking Momentum ⢠Early-Phase Acquisition Fortrea's margin recovery, stronger bookings, and early-phase acquisition support a positive turnaround outlook, though revenue conversion remains the key execution risk.
AI Summary
FTRE is now a high-execution turnaround: improving awards, margins, and positive free cash flow can drive meaningful upside only if backlog converts into sustained revenue growth fast enough to strengthen sub-1x EBIT interest coverage and reduce leverage; otherwise, its $1.12B debt load leaves little room for further sales weakness.
Description
Fortrea Holdings Inc. is a contract research organization that provides development services for biopharmaceuticals and medical devices globally. Its operations are organized into Clinical Services, covering clinical pharmacology and the spectrum of clinical development, and Enabling Services, which supplies patient access, trial technology, randomization and drug supply support. The company delivers these capabilities through full-service, functional service provider and hybrid models and also offers phase IâIV trial management and post-approval support; it was incorporated in 2023 and is based in Durham, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 4 | Dec 11 | FTRE | Fortrea Holdings Inc. | Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management. | Closed | +7.2% |